Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease
- 7 May 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
Abstract
The TAFRO clinical subtype of idiopathic multicentric Castleman disease (iMCD-TAFRO)is a rare hematologic illness involving episodic disease flares of thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly (TAFRO) and progressive multiple organ dysfunction. We previously showed that the mTOR signaling pathway is elevated in lymph nodes of iMCD-TAFRO patients and that an mTOR inhibitor is effective in a small cohort of patients. However, the upstream mechanisms, cell types, and mediators involved in disease pathogenesis remain unknown. Here, we developed a targeted approach to identify candidate cellular drivers and mechanisms in iMCD-TAFRO through cellular and transcriptomic studies. Using paired iMCD-TAFRO PBMC samples collected during flare and remission, we identified T cell activation and alterations in NK cell and monocyte subset frequencies during iMCD-TAFRO flare. These changes were associated with increased Type I IFN (IFN-1) response gene signatures across CD8* T cells, NK cells, and monocytes. Finally, we found that IFN-beta stimulation of monocytes and T cells from iMCD-TAFRO patient remission samples induced increased mTOR activation compared with healthy donors, and this was abrogated with either mTORC1 or JAK1/2 inhibition. The data presented here support a potentially novel role for IFN-1 signaling as a driver of increased mTOR signaling in iMCD-TAFRO.Funding Information
- National Institutes of Health (1R01HL141408-01)
- Perelman School of Medicine, University of Pennsylvania (Hematologic Malignancies Translational Center of Excellence Pilot Grant)
- Perelman School of Medicine, University of Pennsylvania (Penn Center for Precision Medicine Pilot Grant)
- Castleman Disease Collaborative Network (CDCN-2018-003-R)
This publication has 39 references indexed in Scilit:
- International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman diseaseBlood, 2017
- Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndromeScientific Reports, 2017
- Idiopathic multicentric Castleman's disease: a systematic literature reviewThe Lancet Haematology, 2016
- Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV‐8‐negative multicentric Castleman diseaseAmerican Journal of Hematology, 2015
- Use of a claims database to characterize and estimate the incidence rate for Castleman diseaseLeukemia & Lymphoma, 2014
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2014
- Castleman-Kojima Disease (TAFRO Syndrome) : A Novel Systemic Inflammatory Disease Characterized by a Constellation of Symptoms, Namely, Thrombocytopenia, Ascites (Anasarca), Microcytic Anemia, Myelofibrosis, Renal Dysfunction, and Organomegaly : A Status Report and Summary of Fukushima (6 June, 2012) and Nagoya Meetings (22 September, 2012)Journal of Clinical and Experimental Hematopathology, 2013
- The clinical spectrum of Castleman's diseaseAmerican Journal of Hematology, 2012
- Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman diseaseBlood, 2005
- Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 AntibodyThe New England Journal of Medicine, 1994